FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

Little is known about the genomic landscape of FGFR2‐altered gastroesophageal adenocarcinomas. This article attempts to bridge that gap, with a focus on concurrent alterations that may affect sensitivity to FGFR2‐directed therapies.

[1]  S. Klempner,et al.  Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas. , 2019, Cancer Discovery.

[2]  B. Taylor,et al.  EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. , 2018, Cancer discovery.

[3]  Xianglin Yuan,et al.  FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway , 2018, Cellular Physiology and Biochemistry.

[4]  Y. Jeong,et al.  Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor. , 2018, The international journal of biochemistry & cell biology.

[5]  F. López-Ríos,et al.  Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. , 2018, The oncologist.

[6]  M. Aoki,et al.  Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer , 2018, Molecular Cancer Therapeutics.

[7]  Tae-You Kim,et al.  FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro , 2018, Molecular oncology.

[8]  Robert A Gatenby,et al.  Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies , 2017, bioRxiv.

[9]  Chandra Sekhar Pedamallu,et al.  Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. , 2018, Cancer cell.

[10]  J. Chao,et al.  Toward optimizing outcomes in Her2-positive gastric cancer: timing and genomic context matter. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Leah M Chase,et al.  Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. , 2018, Cancer discovery.

[12]  A. Bass,et al.  Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  P. Philip,et al.  Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Y. Miyagi,et al.  Frequent Coamplification of Receptor Tyrosine Kinase and Downstream Signaling Genes in Japanese Primary Gastric Cancer and Conversion in Matched Lymph Node Metastasis , 2018, Annals of surgery.

[15]  David R. Jones,et al.  Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. , 2018, Cancer discovery.

[16]  Andrew Dunford,et al.  Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. , 2018, Cancer discovery.

[17]  G. Pruneri,et al.  Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study , 2017, Clinical Cancer Research.

[18]  M. Teh,et al.  Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β , 2017, Molecular Cancer Therapeutics.

[19]  Y. Bang,et al.  A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[21]  S. Park,et al.  Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2–Amplified Gastric Cancer Patient–Derived Cell Model , 2017, Translational oncology.

[22]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[23]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[24]  Lei Wang,et al.  FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1 , 2017, International journal of oncology.

[25]  S Marsoni,et al.  Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort , 2017, Oncogene.

[26]  Benjamin J. Raphael,et al.  Integrated genomic characterization of oesophageal carcinoma , 2017, Nature.

[27]  Sin-Ho Jung,et al.  FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival , 2016, Modern Pathology.

[28]  Sue Chua,et al.  High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. , 2016, Cancer discovery.

[29]  P. Stephens,et al.  Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors , 2016, Oncoscience.

[30]  Xiaomin Lu,et al.  Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. , 2015, Journal of gastrointestinal oncology.

[31]  Jeffrey W. Clark,et al.  Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. , 2015, Cancer discovery.

[32]  Razelle Kurzrock,et al.  The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.

[33]  P. Stephens,et al.  Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. , 2015, The oncologist.

[34]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[35]  Zhe Zhang,et al.  Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer , 2014, Oncotarget.

[36]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[37]  Daniel V.T. Catenacci,et al.  Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity , 2014, Molecular oncology.

[38]  A. Ochiai,et al.  Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma , 2015, Gastric Cancer.

[39]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[40]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[41]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[42]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[43]  J. Ji,et al.  FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547 , 2013, Clinical Cancer Research.

[44]  Fabrice Andre,et al.  Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. , 2013, Cancer discovery.

[45]  R. Gillies,et al.  Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.

[46]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[47]  Andrew P Thomas,et al.  AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. , 2012, Cancer research.

[48]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.